The ANZICS/ACCCN Annual Scientific Meeting on Intensive Care was held at the Melbourne Convention and Exhibition Centre from October 9th - 11th.
Two of the team members from the Sedation Practice in Intensive Care Evaluation (SPICE III) Program presented at the conference: Dr Yahya Shehabi, Chief Investigator of SPICE III, and Project Manager Belinda Howe, who is also Project Manager for SPICE III and ARISE.
Assoc Prof Sandra Peake, Chair of the Management Committee for Australasian Resuscitation in Sepsis Evaluation (ARISE) trial, presented the preliminary findings which were released a week earlier at the European Society of Intensive Care Medicine (ESICM) annual meeting in Barcelona. The trial showed no benefit from early goal-directed therapy (EGDT) versus standard care, similar findings to the ProCESS trial released less than a year earlier.
Tweets during the presentation such as “Disappointing that @TheARISEstudy didn't improve outcomes, but shows the value of well designed research to guide treatment #ASM14Melb” echoed comments from the ESICM presentation a week earlier “@TheARISEstudy @AndersPerner @ICNARCCTU Thank you all for valuable data which can inform practice. No such thing as a "negative" trial!”
Research Path developed the eCRF and randomisation for ARISE. Patient recruitment commenced in October 2008 and we have enjoyed being involved with the project, and their great team, for the past 6 years.
If you missed the conference, login to Twitter and search for hashtag #asm14melb to see photos of presentation highlights and hear what the audience were saying. Also, you can download the Convenors Podcast.